O26 多糖类作为肠病原性E.中关键参与者 大肠杆菌的免疫逃避和疫苗开发
Thiago Jordão da Silva Lemos1, Herbert Guimarães de Sousa Silva1, José Osvaldo Previato2
1Laboratório de Bacteriologia, Instituto Butantan, Avenida Vital Brasil, 1500, São Paulo 05503-900, SP, Brazil.
肠病原性大肠杆菌 (EPEC) 在囊中使用O26多糖化合物进行免疫逃避,阻碍补充和巨细胞的反应. 反O26抗体中和这种保护和EPEC粘附,表明O26多糖类作为疫苗抗原.
科学领域:
- 微生物学 微生物学
- 免疫学 免疫学 免疫学
- 细菌学 细菌学是一门学科.
背景情况:
- 肠病原性大肠杆菌 (EPEC) 生产的囊与脂多糖 (LPS) 的O-抗原多糖相同.
- 囊中的多糖在细菌的免疫逃避策略中起作用.
研究的目的:
- 为了研究O26多糖在囊化O26EPEC的免疫逃避机制的影响.
- 为了比较封装O26 EPEC和非封装输血性大肠杆菌 (E. coli) 之间的免疫逃避.
主要方法:
- 在EPEC和EHEC中量化特定的糖残留物 (糖,葡萄糖,肝糖,N-乙糖胺).
- 评估补充C3b沉积和细菌溶解.
- 对巨细胞的细胞化和细菌对上皮细胞的粘附的评估.
- 对抗O26多糖体抗体的影响分析.
主要成果:
- 与EHEC相比,EPEC显示的葡萄糖,肝糖和N-乙烯基葡萄糖胺水平显著更高.
- EPEC囊抑制了C3b沉积和补充介导的溶解.
- 囊式EPEC表现出对巨细胞消化酶的耐药性.
- 反O26抗体克服了囊介导的免疫逃避,并抑制了细菌粘附.
结论:
- O26多糖类通过防止补体激活和细胞分裂,对EPEC免疫逃避有显著的贡献.
- 反O26多糖抗体可以中和EPEC的免疫逃避策略和粘附.
- O26多糖是开发针对封装EPEC菌株的疫苗的有希望的候选人.
更多相关视频
13:47Opsono-Adherence Assay to Evaluate Functional Antibodies in Vaccine Development Against Bacillus anthracis and Other Encapsulated Pathogens
Published on: May 19, 2020
05:31Purification and Visualization of Lipopolysaccharide from Gram-negative Bacteria by Hot Aqueous-phenol Extraction
Published on: May 28, 2012
相关概念视频
Defense Against Bacterial Pathogens
Phagocytes
Phagocytes are the frontline soldiers of the immune system. They include neutrophils and macrophages. Neutrophils are the most abundant type of white blood cell and are quickly mobilized to the site of infection. Macrophages are larger cells that patrol...
Vaccinations
Oligosaccharide Assembly
Multiple sugar molecules that may or may...
Cellulose and Pectic Polysaccharides
As a cell matures, its cell wall specializes according to its type. For example, the...
Glycocalyx and its Functions
